Generation Bio to Present at the Needham 24th Annual Virtual Healthcare Conference
Rhea-AI Summary
Generation Bio (Nasdaq: GBIO), a biotechnology company focused on T cell-driven autoimmune diseases, has announced its participation in the upcoming 24th Annual Needham Virtual Healthcare Conference.
The company's President and CEO, Geoff McDonough, M.D., will engage in a fireside chat scheduled for Wednesday, April 9th at 12:45 p.m. ET. Investors and interested parties can access the live webcast through the investor section at investors.generationbio.com, where a replay will remain available for 30 days after the event.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, GBIO gained 0.57%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate in a fireside chat at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9th at 12:45 p.m. ET.
A live webcast of the presentation will be available on the investor section of the company’s website at investors.generationbio.com. A replay will be available there for 30 days following the event.
About Generation Bio
Generation Bio is a biotechnology company working to change what’s possible for people living with T cell-driven autoimmune diseases. The company is developing redosable therapeutics that reprogram T cells in vivo to reduce or eliminate the production and persistence of autoreactive T cells, which erroneously recognize and attack the body’s own tissues, causing autoimmune diseases. Generation Bio’s innovative approach leverages cell-targeted lipid nanoparticles (ctLNP) to selectively deliver small interfering RNA (siRNA) to T cells. This combination of selective delivery and an intracellular, genetically precise mechanism of target engagement could unlock a series of high-value, historically undruggable disease-driving genes in autoimmunity.
For more information, please visit www.generationbio.com.
Investors and Media Contact
Maren Killackey
Generation Bio
mkillackey@generationbio.com
857-371-4638
FAQ
When is Generation Bio (GBIO) presenting at the Needham Healthcare Conference 2025?
How can investors watch Generation Bio's (GBIO) Needham Conference presentation?
How long will Generation Bio's (GBIO) Needham Conference presentation be available for replay?
What is Generation Bio's (GBIO) current therapeutic focus?
